TransMedics Group, Inc.

TMDX Healthcare Medical Devices

TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.

Revenue
+41.2%
EPS
−31.0%
Free cash flow
−55.4%
Total debt
−89.3%

Quarter to September 2026, against a year earlier

85.08 16.10 +23.34%
Market cap
$2.4B
P/E
16.4×
Fwd P/E
49.4×
Dividend yield
—
F-score
7/9
Altman Z
5.32
Beneish M
−1.32
Dividend safety
n/a

TransMedics Group, Inc. (TMDX) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, TransMedics Group, Inc. (TMDX) trades at a P/E ratio of 16.4×. Over the past ten years it has ranged from 0.0× (June 2024) to 2,201× (August 2024); the current reading is higher than 72% of that period. That is below the Medical Devices industry median of 25.6× and below the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 21.8× (62.59%)
FY2024 58.3× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 19.9× 32.22%
Jun 2026 15.0× (23.97%)
Mar 2026 19.8× (9.35%)
Dec 2025 21.8× (47.54%)
31 more quarters

Against its own ten years

Low 0.0× High 2,201×
Ten-year median 0.0×
Current reading's percentile 72

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on TMDX